LYZZ Capital is a leading global healthcare-dedicated VC/PE firm. We currently are actively investing out of USD and RMB funds totaling over USD$460 million. The LYZZ team is composed of highly experienced investment and operating professionals from leading pharmaceutical/biotech companies and Wall Street firms with strong scientific and medical professionals background. We’ve worked together for over a decade and have cultivated a cordial, flat and team-oriented working environment. Our team’s biotech investment experience extends back over 15 years, with more 10 years of presence in China alone. We invest in talents, assets and technologies globally, with an emphasis on unmet medical needs and large market potential in China.
Location: China, Shanghai
Employees: 11-50
Founded date: 2014
Investment Type: Venture Capital
Mentions in press and media 2
| Date | Title | Description | Source |
| 23.06.2022 | Mojia Biotech Completes Series B Financing to Advance Manufa... | SHANGHAI, June 23, 2022 /PRNewswire/ -- Mojia Biotech, a Shanghai-based leading bio-manufacturing co... | en.prnasia... |
| 12.01.2021 | Baird Capital Invests in Jumpcode Genomics | Baird Capital announced today that its venture team has completed an investment in Jumpcode Genomics... | bairdcapit... |